Bristol/Merck's Pargluva Combination Use With Sulfonylureas Not Recommended
This article was originally published in The Pink Sheet Daily
Executive Summary
Committee supports use of the type 2 diabetes therapy muraglitazar as monotherapy and in combination with metformin, but says safety with sulfonylureas has not been adequately studied.
You may also be interested in...
Pargluva Rejection Urged By Public Citizen
FDA advisory committee's recommendation for approval of Bristol-Myers Squibb's diabetes agent was "inappropriate" because it was based on "vague promises" from industry, Public Citizen says in a letter to the agency.
Pargluva Rejection Urged By Public Citizen
FDA advisory committee's recommendation for approval of Bristol-Myers Squibb's diabetes agent was "inappropriate" because it was based on "vague promises" from industry, Public Citizen says in a letter to the agency.
Pargluva Development May Be Terminated By Bristol, Merck
Regulatory approval and commercial success of the investigational type 2 diabetes drug will require additional clinical trials that could take up to five years to complete, Bristol says.